Virus-like particle vaccine could offer protection against chikungunya virus
January 29th, 2010 - 1:58 pm ICT by ANI ( Leave a comment )London, Jan 29 (ANI): Using non-infectious virus-like particles (VLP), researchers at the National Institutes of Health have developed an experimental vaccine that could successfully protect macaques and mice against chikungunya virus.
Chikungunya virus is a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain.
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) developed the vaccine because there is no vaccine or treatment for chikungunya virus infection.
“Increases in global travel and trade, and possibly climate change, may be contributing to the spread of disease-carrying mosquitoes into new areas. Finding safe and effective human vaccines for chikungunya virus and other insect-borne pathogens is an important global health priority,” Nature quoted NIAID Director Dr. Anthony S. Fauci as saying.
To develop the vaccine, scientists in NIAID’s Vaccine Research Center (VRC) identified the proteins that give rise to chikungunya VLPs.
The VLPs mimic actual virus particles but cannot cause infection, so they can be used safely as a vaccine to elicit immune responses.
The researchers immunized rhesus macaques with the VLPs, waited 15 weeks before exposing the animals to chikungunya virus, and observed that the vaccine provided complete protection from infection.
When the group found that antibodies were responsible for immune protection, they transferred antibody-containing serum from the vaccinated macaques to mice with deficient immune systems.
The mice then were exposed to a lethal dose of chikungunya virus, but the immune serum protected them from infection.
“This virus-like particle vaccine provides a promising way to protect against an emerging infectious disease threat. This same approach could possibly extend to viruses related to chikungunya that cause fatal diseases such as encephalitis,” said VRC Director Dr. Gary Nabel.
Nabel said his group plans to seek approval for clinical trials to further evaluate the safety and efficacy of the vaccine in humans.
The details about the vaccine were published in the online version of Nature Medicine. (ANI)
- Experimental vaccine shows promise against chikungunya - Mar 05, 2010
- Human vaccine for chikungunya virus a step closer - Feb 07, 2010
- Vaccine-delivering nanoparticles may help fight HIV, malaria - Feb 23, 2011
- Vaccine offers hope to treat chikungunya - Aug 14, 2011
- Universal influenza vaccine 'on the anvil' - Dec 07, 2010
- Antibodies that prevent HIV from infecting human cells found - Jul 09, 2010
- Vaccines to boost immunity where it counts - Jan 23, 2012
- Oral vaccines are 'alternative to jab' - Feb 11, 2011
- Scientists 1 step closer to developing treatment for chikungunya - Feb 16, 2011
- Once-in-a-lifetime flu jab that fights off all strains to be available 'within 5yrs' - Nov 16, 2010
- Soon, nasal spray vaccines to curb flu - Apr 12, 2011
- Novel vaccine strategy may offer protection against flu viruses - May 19, 2009
- 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus - Jun 16, 2010
- One-time jab to protect against all flu strains - Nov 16, 2010
- Experimental vaccine protects monkeys from Ebola virus - May 22, 2010
Tags: anthony s fauci, borne pathogen, disease threat, dr anthony, emerging infectious disease, experimental vaccine, fatal diseases, human vaccines, immune protection, immune serum, infection increases, infectious virus, lethal dose, london jan, macaques, national institute of allergy and infectious diseases, national institutes of health, vaccine research center, virus infection, virus particles
